Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 10;10(17):e35901.
doi: 10.1016/j.heliyon.2024.e35901. eCollection 2024 Sep 15.

IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer

Ling Xu  1 , Peng Cao  1 , Jianpeng Wang  2 , Peng Zhang  1 , Shuhui Hu  1 , Chao Cheng  1 , Hua Wang  3
Affiliations
Review

IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer

Ling Xu et al. Heliyon. .

Abstract

Lung cancer, one of the most prevalent cancers worldwide, stands as the primary cause of cancer-related deaths. As is well-known, the utmost crucial risk factor contributing to lung cancer is smoking. In recent years, remarkable progress has been made in treating lung cancer, particularly non-small cell lung cancer (NSCLC). Nevertheless, the absence of effective and accurate biomarkers for diagnosing and treating lung cancer remains a pressing issue. Interleukin 22 (IL-22) is a member of the IL-10 cytokine family. It exerts biological functions (including induction of proliferation and anti-apoptotic signaling pathways, enhancement of tissue regeneration and immunity defense) by binding to heterodimeric receptors containing type 1 receptor chain (R1) and type 2 receptor chain (R2). IL-22 has been identified as a pro-cancer factor since dysregulation of the IL-22-IL-22R system has been implicated in the development of different cancers, including lung, breast, gastric, pancreatic, and colon cancers. In this review, we discuss the differential expression, regulatory role, and potential clinical significance of IL-22 in lung cancer, while shedding light on innovative approaches for the future.

Keywords: Biomarker; IL-22; Inflammation immunology; Lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
IL-22 plays four main functions during the progression of lung cancer. 1) Promote lung cancer cell proliferation and invasion, and inhibit lung cancer cell apoptosis; 2) Regulate the abundance of immune cells in lung cancer tissues and activate the inflammatory microenvironment; 3) Promote cancer angiogenesis; 4) Activate lung cancer stem cells.
Fig. 2
Fig. 2
IL-22 induces NK cells to overexpress CD155, which binds to NK cell activation receptor CD226. Over-activation leads to a decrease in the amount of CD226 and impaired NK cell function, thereby mediating tumor cell immune escape.
Fig. 3
Fig. 3
IL-22 promotes the proliferation, migration and epithelial-mesenchymal transition of lung cancer cells through PI3K/AKT, JAK-STAT3, p38 MAPK and other signaling pathways, and antagonizes the apoptosis of lung cancer cells induced by anti-tumor drugs.
Fig. 4
Fig. 4
Crispr-cas13-based IL-22 mRNA editing can be utilized for lung cancer therapy by combining with emerging technologies such as single-base editing and single-cell sequencing.
Fig. 5
Fig. 5
Precision delivery of various nanomaterials containing IL-22 related drugs for the treatment of lung cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lareau S., Slatore C., Smyth R. Lung cancer. Am. J. Respir. Crit. Care Med. 2021;204(12):P21–P22. - PubMed
    1. Huang J., Deng Y., Tin M.S., Lok V., Ngai C.H., Zhang L., et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest. 2022;161(4):1101–1111. - PubMed
    1. Bade B.C., Dela Cruz C.S. Lung cancer 2020: epidemiology, etiology, and prevention. Clin. Chest Med. 2020;41(1):1–24. - PubMed
    1. Malhotra J., Malvezzi M., Negri E., La Vecchia C., Boffetta P. Risk factors for lung cancer worldwide. Eur. Respir. J. 2016;48(3):889–902. - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71(3):209–249. - PubMed

LinkOut - more resources